Arunjyoti Bio Ventures Faces Intense Selling Pressure Amid Consecutive Losses

On 19 Nov 2025, Arunjyoti Bio Ventures witnessed a day change of -1.95%, underperforming the Sensex which posted a positive 0.25% gain. This stark contrast highlights the stock’s vulnerability amid broader market resilience. The absence of buyers today underscores an extreme selling scenario, often indicative of investor apprehension or reaction to underlying concerns.

Examining the short-term performance, the stock has declined by -9.42% over the past week, while the Sensex recorded a modest 0.49% increase. The one-month figures show a similar trend with Arunjyoti Bio Ventures falling -10.57% against the Sensex’s 1.11% rise. These figures reflect a sustained period of selling pressure that has not been mirrored by the broader market or sector indices.

Despite the recent downward trajectory, the stock’s three-month performance shows a remarkable 80.24% gain, significantly outpacing the Sensex’s 3.96% rise during the same period. This disparity suggests that while the stock has delivered strong returns over the medium term, the current phase is marked by intense selling and correction.

Longer-term data presents a mixed picture. Over one year, Arunjyoti Bio Ventures has declined by -14.92%, contrasting with the Sensex’s 9.41% gain. Year-to-date figures are more pronounced, with the stock down -47.57% while the Sensex advanced 8.63%. Over three years, the stock’s performance is flat at 0.00%, whereas the Sensex appreciated by 37.65%. However, over five and ten years, Arunjyoti Bio Ventures has delivered extraordinary returns of 7,130.73% and 2,792.29% respectively, far exceeding the Sensex’s 94.68% and 228.46% gains. These long-term figures highlight the company’s historical growth but do not mitigate the current selling pressure.

From a technical standpoint, the stock is trading below its 5-day and 20-day moving averages, indicating short-term weakness. However, it remains above the 50-day, 100-day, and 200-day moving averages, suggesting that the longer-term trend has not yet been breached. This technical setup may be contributing to the cautious sentiment among investors, as the stock navigates a critical juncture.

Notably, Arunjyoti Bio Ventures has recorded a consecutive fall over the last eight days, with cumulative returns declining by -14.61% during this period. This sustained downward movement, combined with the absence of buyers today, signals distress selling and heightened risk perception among market participants.

Arunjyoti Bio Ventures holds a Mojo Score of 28.0 as of 19 Nov 2025, reflecting a revision in its evaluation to a strong sell grade from a previous sell grade dated 09 Oct 2025. The market capitalisation grade stands at 4, indicating its relative size within the NBFC sector. These metrics provide a quantitative backdrop to the observed market behaviour and selling pressure.

In summary, Arunjyoti Bio Ventures is currently under significant selling pressure, with no buyers recorded today and a series of consecutive losses over the past eight days. The stock’s underperformance relative to the Sensex and its sector highlights a challenging environment for investors. While the longer-term performance has been historically strong, the immediate outlook is marked by distress selling signals and technical weakness.

Investors monitoring Arunjyoti Bio Ventures should carefully consider these factors in the context of broader market conditions and sector dynamics. The current scenario underscores the importance of vigilance and thorough analysis when evaluating stocks exhibiting extreme selling pressure and consecutive declines.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →